TIL vs. PSTX, GNFT, ADAP, BDTX, MGX, IPSC, CADL, IPHA, IVVD, and CHRS
Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Poseida Therapeutics (PSTX), Genfit (GNFT), Adaptimmune Therapeutics (ADAP), Black Diamond Therapeutics (BDTX), Metagenomi (MGX), Century Therapeutics (IPSC), Candel Therapeutics (CADL), Innate Pharma (IPHA), Invivyd (IVVD), and Coherus BioSciences (CHRS). These companies are all part of the "biological products, except diagnostic" industry.
Instil Bio (NASDAQ:TIL) and Poseida Therapeutics (NASDAQ:PSTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.
Instil Bio has a net margin of 0.00% compared to Poseida Therapeutics' net margin of -131.95%. Instil Bio's return on equity of -51.27% beat Poseida Therapeutics' return on equity.
Instil Bio currently has a consensus target price of $25.00, suggesting a potential upside of 133.64%. Poseida Therapeutics has a consensus target price of $14.67, suggesting a potential upside of 445.23%. Given Poseida Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Poseida Therapeutics is more favorable than Instil Bio.
In the previous week, Poseida Therapeutics had 2 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for Poseida Therapeutics and 0 mentions for Instil Bio. Poseida Therapeutics' average media sentiment score of 0.96 beat Instil Bio's score of 0.00 indicating that Poseida Therapeutics is being referred to more favorably in the news media.
Poseida Therapeutics has higher revenue and earnings than Instil Bio. Poseida Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.
Instil Bio received 60 more outperform votes than Poseida Therapeutics when rated by MarketBeat users. However, 65.38% of users gave Poseida Therapeutics an outperform vote while only 52.51% of users gave Instil Bio an outperform vote.
Instil Bio has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Poseida Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.
60.6% of Instil Bio shares are held by institutional investors. Comparatively, 46.9% of Poseida Therapeutics shares are held by institutional investors. 46.5% of Instil Bio shares are held by company insiders. Comparatively, 2.9% of Poseida Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Poseida Therapeutics beats Instil Bio on 9 of the 17 factors compared between the two stocks.
Get Instil Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Instil Bio Competitors List
Related Companies and Tools
